现代蛋白酶抑制剂使用与HIV感染者新发慢性肾病风险:D:A:D研究
基于D:A:D队列随访至2016年2月1日,采用校正泊松回归分析HIV感染者使用利托那韦增效阿扎那韦(ATV/r)或达芦那韦(DRV/r)与新发慢性肾病(CKD)的关联。
要点
- ATV/r累积暴露越长,CKD发生率逐渐升高
- DRV/r使用与新发CKD无显著关联
- HIV感染者使用ATV/r时需关注肾功能监测
核心结论
- ATV/r使用与CKD风险显著相关且随暴露时间增加而升高,DRV/r使用未显示显著关联。
研究设计与样本
- D:A:D研究队列随访至CKD发生、末次访视后6个月或2016年2月1日,采用校正泊松回归分析。
主要发现
- CKD发生率为10.0/1000人年(95%CI 9.5-10.4),随ATV/r暴露增加逐渐升高,DRV/r关系不明确。
临床怎么用
- HIV感染者选用蛋白酶抑制剂时,应结合CKD风险权衡ATV/r与DRV/r,ATV/r使用期间加强肾功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. METHODS: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). RESULTS: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD. CONCLUSION: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
引用
- Ryom L, Dilling Lundgren J, Reiss P, et al. Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. J Infect Dis. 2019. PMID: 31504669. doi:10.1093/infdis/jiz369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。